Fulltext

Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy

Giovacchini, Giampiero ; Nicolas, Guillaume ; Freidank, Heike ; Mindt, Thomas ; Forrer, Flavio

In: European Journal of Nuclear Medicine and Molecular Imaging, 2011, vol. 38, no. 9, p. 1675-1682

Zum persönliche Liste hinzufügen
    Titel
    • Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy
    Autor
    • Giovacchini, Giampiero. Department of Radiology and Nuclear Medicine, Division of Endocrine Diagnostics and Radionuclide Therapy, University Hospital Basel, 4031, Basel, Switzerland
    • Nicolas, Guillaume. Department of Radiology and Nuclear Medicine, Division of Endocrine Diagnostics and Radionuclide Therapy, University Hospital Basel, 4031, Basel, Switzerland
    • Freidank, Heike. Laboratory Medicine, University Hospital Basel, Basel, Switzerland
    • Mindt, Thomas. Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    • Forrer, Flavio. Department of Radiology and Nuclear Medicine, Division of Endocrine Diagnostics and Radionuclide Therapy, University Hospital Basel, 4031, Basel, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • European Journal of Nuclear Medicine and Molecular Imaging, 2011, vol. 38, no. 9, p. 1675-1682. Springer-Verlag
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:315256
    Summary
    Purpose: Administration of positively charged amino acids has been introduced to reduce the nephrotoxicity of targeted radiopeptide therapy (TRT). However, the amino acid solution may have side effects, including hyperkalaemia. The aim of this study was to evaluate the frequency and the magnitude of hyperkalaemia in neuroendocrine tumour (NET) patients undergoing TRT. Methods: Enrolled in the study were 31 patients with NET eligible for TRT with [90Y-DOTA(0),Tyr(3)]octreotide (90Y-DOTATOC). Their mean age was 54 ± 14years. Of these 31 patients, 21 (67%) were referred for the first treatment cycle, while 10 (33%) were referred for a subsequent therapy cycle. Patients were treated with therapeutic doses of 90Y-DOTATOC ranging from 7,030 to 35,520MBq. To inhibit tubular reabsorption of 90Y-DOTATOC, 1l of physiological saline solution containing 25g of arginine hydrochloride and 25g of lysine hydrochloride was given over 4h starting 1h before 90Y-DOTATOC injection. All patients underwent a standard biochemical blood analysis at baseline, and 4h and 24h after the beginning of the amino acid infusion. Results: ANOVA repeated measures showed a significant overall effect on K+ levels over time (F = 118.2, df = 2, P < 0.0001). Mean serum levels of K+ were 4.00 ± 0.33mmol/l at baseline, 5.47 ± 0.57mmol/l at 4h, and 4.38 ± 0.63mmol/l at 24h after the beginning of the infusion. Post-hoc analysis showed that K+ levels at 4h were significantly (P < 0.05) higher than at baseline. K+ levels at 24h were significantly (P < 0.05) lower than at 4h but they were still significantly (P < 0.05) higher than K+ levels at baseline. On a subject-by-subject basis, none of the 31 patients had increased K+ levels at baseline. At 4h, 24 of the 31 patients (77%) had K+ levels above the normal range, and 6 patients (19%) experienced severe hyperkalaemia (K+ ≥ 6mmol/l). All patients with increased K+ levels were clinically asymptomatic. At 24h, only 4 patients (13%) had increased K+ serum levels. The magnitude of the increase in K+ levels between baseline and 4h was relatively homogeneous over the whole group (1.41 ± 0.50mmol/l) and it was not related (linear regression, P>0.05) to baseline K+ levels. Intravenous administration of 40mg furosemide 1h after the beginning of the amino acid infusion did not have a significant effect on K+ levels (P>0.05). No clinical characteristic was predictive for the increase in K+ levels (chi-squared test, P > 0.05). Conclusion: Hyperkalaemia is a frequent, potentially life-threatening side effect of basic amino acid infusion during TRT. K+ levels 4h after the beginning of the infusion should be monitored in patients at risk of complications, such as those with heart disease and those with risk factors for nephrotoxicity